论文部分内容阅读
目的观察大剂量阿托伐他汀治疗急性心肌梗死(AMI)溶栓后对患者血浆BNP的影响。方法选取医院诊断为AMI并溶栓成功的患者52例,随机分为治疗组和对照组各26例;治疗组给予常规治疗及阿托伐他汀80mg/d。对照组给予常规治疗及阿托伐他汀20mg/d。观察溶栓前及溶栓后7d血浆C反应蛋白(CRP)、B型尿钠肽(BNP)的水平。结果溶栓前2组患者CRP、BNP比较无统计学意义(P>0.05);治疗7d后治疗组与对照组比较,CRP、BNP水平较前均降低,差异有统计学意义(P<0.05)。2组患者治疗过程中,均无明显不良反应发生。结论AMI患者早期应用大剂量阿托伐他汀能够明显降低血浆CRP及BNP水平,抑制神经、内分泌系统的激活,减轻炎性反应,起到心脏保护作用。
Objective To observe the effects of high-dose atorvastatin on plasma BNP in patients with acute myocardial infarction (AMI) thrombolysis. Methods Totally 52 patients diagnosed as AMI with successful thrombolysis were randomly divided into treatment group (26 cases) and control group (26 cases). The treatment group received conventional therapy and atorvastatin (80mg / d). The control group was given routine treatment and atorvastatin 20mg / d. The levels of plasma C-reactive protein (CRP) and B-type natriuretic peptide (BNP) before and after thrombolysis were observed. Results There was no significant difference in CRP and BNP between the two groups before thrombolysis (P> 0.05). After 7 days of treatment, the levels of CRP and BNP in treatment group and control group were lower than those in the former group (P <0.05) . Two groups of patients in the course of treatment, no significant adverse reactions. Conclusions Early use of large doses of atorvastatin in patients with AMI can significantly reduce the levels of plasma CRP and BNP, inhibit the activation of the nervous and endocrine systems, and reduce the inflammatory response, thus playing a role of cardioprotection.